Probes For Detection Of Animal Nucleotide Sequences Patents (Class 536/24.31)
-
Patent number: 8691786Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: GrantFiled: January 24, 2013Date of Patent: April 8, 2014Assignees: City of Hope, Integrated DNA Technologies, Inc.Inventors: John J. Rossi, Mark A. Behlke, Dongho Kim
-
Publication number: 20140094379Abstract: A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer.Type: ApplicationFiled: January 25, 2012Publication date: April 3, 2014Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Denis Paul Harkin, Vitali Proutski, Julie Black, Peter Kerr, Richard Kennedy, Andreas Winter, Timothy Davison, Max Bylesjo, Vadim Farztdinov, Claire Wilson, Robert James Holt
-
Patent number: 8686127Abstract: This invention relates to an agent, a composition and a product comprising at least one apoptosis-inducing substance, and at least one substance which inhibits expression and/or activity of an apoptosis-inhibiting substance; a method for inducing apoptosis or for treating a proliferative disease using one or more of them; a nucleic acid construct comprising a nucleic acid molecule encoding a protein to be expressed and a nucleic acid molecule which inhibits expression of an undesired protein; and a method for expressing a desired protein in a cell while inhibiting the expression of an undesired protein.Type: GrantFiled: April 13, 2009Date of Patent: April 1, 2014Assignee: LSIP, LLCInventors: Masashi Idogawa, Yasushi Sasaki, Takashi Tokino
-
Publication number: 20140087965Abstract: The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicants: SNU R&DB FOUNDATION, LG ELECTRONICS INC.Inventors: Yunhee KU, Youngsoo KIM, Seungyeon SONG, Jonghwa JIN, Moosub KIM, Yongju YANG
-
Publication number: 20140087967Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.Type: ApplicationFiled: October 25, 2013Publication date: March 27, 2014Applicants: Mor Research Applications, Rosetta Genomics Ltd.Inventors: Yaron GOREN, Shlomit Gilad, Moshe Hod, Yariv Yogev
-
Publication number: 20140087380Abstract: The present invention provides a probe for detecting a mutation in the ALK gene, which is at least one fluorescently labeled oligonucleotide selected from the group consisting of P1 to P4, P7 and P8 oligonucleotides; an application thereof; and an oligonucleotide for the application.Type: ApplicationFiled: September 18, 2013Publication date: March 27, 2014Applicant: ARKRAY, Inc.Inventor: Kaoru Kurose
-
Publication number: 20140088169Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.Type: ApplicationFiled: April 23, 2013Publication date: March 27, 2014Applicant: University of Pittsburgh - of the CommonWealth System of Higher EducationInventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Hijang
-
Publication number: 20140087966Abstract: Methods of detecting D. gatoi or D. cati, are disclosed. A sample suspected of containing a nucleic acid of D. gatoi or D. cati is screened for the presence or absence of that nucleic acid. The presence of the D. gatoi or D. cati nucleic acid indicates the presence of D. gatoi or D. cati. Determining whether the D. gatoi or D. cati nucleic acid is present in the sample can be accomplished by detecting hybridization between a D. gatoi or D. cati probe. Probes and primers for the detection of D. gatoi or D. cati are also disclosed. Disclosed are isolated nucleic acids that encode a D. gatoi or D. cati rRNA gene sequence. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: ApplicationFiled: September 27, 2013Publication date: March 27, 2014Inventors: Stephen A. Kania, Linda A. Frank
-
Patent number: 8679758Abstract: The presently claimed invention provides for novel methods and kits for analyzing a collection of target sequences in a nucleic acid sample. A sample is amplified under conditions that enrich for a subset of fragments that includes a collection of target sequences. The invention further provides for analysis of the above sample by hybridization to an array, which may be specifically designed to interrogate the collection of target sequences for particular characteristics, such as, for example, the presence or absence of one or more polymorphisms.Type: GrantFiled: August 6, 2012Date of Patent: March 25, 2014Assignee: Affymetrix, Inc.Inventors: Hajime Matsuzaki, Xing Su, Sean Walsh, Giulia Kennedy, Rui Mei
-
Patent number: 8680258Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: GrantFiled: November 25, 2009Date of Patent: March 25, 2014Assignee: Alphavax, Inc.Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
-
Publication number: 20140079718Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: Northwestern UniversityInventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
-
Publication number: 20140080132Abstract: A method for predicting ADCC activity in a subject, the method comprising the steps of: (a) preparing a biological sample from the subject, said sample including a leukocyte, (b) bringing a portion of the biological sample and an antibody into contact with each other, (c) detecting expression of at least one marker of ADCC activity selected from the group consisting of tumor necrosis factor super family 15, chemokine CXCL3, and interleukin 6 in the leukocyte in (i) the portion of the sample brought into contact with the antibody and in (ii) another portion of the sample not brought into contact with the antibody, (d) comparing an expression level in portion (i) with the expression level in portion (ii); and (e) predicting presence of the cytotoxic activity when the expression level in portion (i) is higher than the expression level in portion (ii)Type: ApplicationFiled: September 16, 2013Publication date: March 20, 2014Inventors: Kazuhiko Obara, Hiroshi Izutsu, Masato Mitsuhashi, Fumiaki Koizumi, Kenji Tamura, Mayu Yunokawa, Yasuo Kodera, Fumiko Taguchi
-
Patent number: 8673875Abstract: The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector.Type: GrantFiled: December 11, 2012Date of Patent: March 18, 2014Assignee: Kaohsiung Medical UniversityInventors: Suh-Hang Hank Juo, Yung-Song Wang
-
Patent number: 8673632Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.Type: GrantFiled: March 17, 2010Date of Patent: March 18, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Rosanne M. Crooke, Mark J. Graham
-
Publication number: 20140072957Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: February 11, 2013Publication date: March 13, 2014Applicant: Celera CorporationInventors: Hongjin HUANG, Michele CARGILL
-
Publication number: 20140072973Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described.Type: ApplicationFiled: September 12, 2013Publication date: March 13, 2014Inventors: B. Maria H. Eriksson, Francis S. Collins, Leslie B. Gordon, William Ted Brown
-
Patent number: 8669102Abstract: Disclosed herein are compounds and methods for decreasing PrP and preventing, ameliorating, or treating a prion disease or conformational neurodegenerative disorder, in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to PrP include Creutzfeldt-Jakob disease (CJD); variant Creutzfeldt-Jakob Disease (vCJD); Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia; kuru; Bovine Spongiform Encephalopathy (BSE), e.g. “mad cow disease”; Chronic Wasting Disease (CWD); scrapie; transmissible mink encephalopathy; feline spongiform encephalopathy; ungulate spongiform encephalopathy; Alzheimer's disease; Parkinson's disease; Huntington's disease; and Amyotrophic Lateral Sclerosis (ALS).Type: GrantFiled: August 14, 2009Date of Patent: March 11, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Gene Hung, Susan M. Freier, Kenneth W. Dobie
-
Patent number: 8669239Abstract: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity.Type: GrantFiled: August 10, 2012Date of Patent: March 11, 2014Assignee: Ann & Robert H. Lurie Children's Hospital of ChicagoInventors: Mary Jessica Hendrix, Lynne-Marie Postovit, Richard Edward Barnet Seftor, Elisabeth Ann Seftor
-
Publication number: 20140065167Abstract: Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and active fragments, monomers and combinations thereof having one or more of the following characteristics: capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, and active fragments thereof.Type: ApplicationFiled: March 13, 2013Publication date: March 6, 2014Inventors: Moses Rodriguez, David J. Miller, Larry R. Pease
-
Patent number: 8664189Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: GrantFiled: September 22, 2009Date of Patent: March 4, 2014Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Publication number: 20140057797Abstract: The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.Type: ApplicationFiled: June 2, 2013Publication date: February 27, 2014Applicant: Board of Regents, The University of Texas SystemInventors: Jonathan C. Cohen, Helen H. Hobbs
-
Publication number: 20140057966Abstract: Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.Type: ApplicationFiled: November 7, 2013Publication date: February 27, 2014Applicants: Albert Einstein College of Medicine of Yeshiva University, IFO-Regina Elena Cancer Institute, Massachusetts Institute of TechnologyInventors: John S. Condeelis, Sumanta Goswami, Frank Gertler, Paola Nistico
-
Publication number: 20140057802Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.Type: ApplicationFiled: March 23, 2012Publication date: February 27, 2014Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Fang Liu, Xia Meng, Bruno Mougin
-
Publication number: 20140058000Abstract: The present invention relates to a method for predisposition prediction of a subject to the development of cervical cancer and/or cancer precursors in an infection with the human papilloma virus (HPV) and/or for the detection of a persistent HPV infection, the method comprising the steps of obtaining a sample from the subject; and detecting at least one of the diagnostic markers or fragments thereof listed in Table 1 in the sample obtained from the subject.Type: ApplicationFiled: November 4, 2013Publication date: February 27, 2014Applicant: Eberhard-Karls-Universitaet Tuebingen Universitaet UniversitaetsklinikumInventors: Thomas Iftner, Frank Stubenrauch, Anna Manawapat, Susanne Krueger Kjaer
-
Patent number: 8658783Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.Type: GrantFiled: April 13, 2012Date of Patent: February 25, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Susan M. Freier
-
Publication number: 20140051082Abstract: The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.Type: ApplicationFiled: April 19, 2012Publication date: February 20, 2014Inventors: Michal Schweiger, Hans Lehrach, Stefan Sörnö, Thorsten Schlomm, Holger Sültmann, Guido Suter
-
Publication number: 20140050803Abstract: Described herein are compositions and methods for the prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma or with melanoma brain tropism, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: ApplicationFiled: April 13, 2011Publication date: February 20, 2014Applicant: NEW YORK UNIVERSITYInventors: Eva Hernando, Moshe Hoshen, Iman Osman, Avital Gaziel-Sovran, Miguel F. Segura
-
Publication number: 20140051587Abstract: Hence, the invention relates to a method for diagnosis and/or prognosis of cancer, comprising the steps of analyzing in a sample of a subject the DNA methylation status of a genomic region of at least one member of the group of, (i) SFN according to SEQ ID NO. 1, (ii) SLIT2 according to SEQ ID NO. 2, (iii) SERPINB5 according to SEQ ID NO. 3; and (iv) TWIST 1 according to SEQ ID NO 4; wherein, if (i) SFN shows a methylation cut off value of above 80% and/or, (ii) SLIT2 shows a methylation cut-off value of above 45% and/or, (iii) SERPBINB5 shows a methylation cut-off value of above 70%, and/or (iv) TWIST 1 shows a methylation level below 15% the sample is categorized as a sample from a patient with cancer and/of a poor prognosis.Type: ApplicationFiled: March 30, 2012Publication date: February 20, 2014Applicant: QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDONInventor: Attila Lorincz
-
Publication number: 20140045853Abstract: Aspects of the invention relate to methods of treatment, and to kits and systems for the same including materials for determining that an individual is susceptible to cancer and if warranted treating the patient of cancer or initiating a monitoring strategy and/or taking a preventive action. Therapeutic and preventive interventions include, treating the patient with a PARR inhibitors and/or laprascopic oophorectomy. The invention also relates to systems and methods of genotyping an individual, and to methods of identifying a patent with a higher than normal likelihood of developing cancer and/or genetically related individuals or groups at heighten risk for developing cancer, particularly ovarian cancer.Type: ApplicationFiled: August 6, 2013Publication date: February 13, 2014Inventor: Sabera Nazneen Rahman
-
Publication number: 20140044645Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: ApplicationFiled: September 9, 2013Publication date: February 13, 2014Applicant: Genentech, Inc.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Publication number: 20140045180Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: ApplicationFiled: December 16, 2011Publication date: February 13, 2014Applicant: GenomicTree, Inc.Inventors: Sung Whan An, Tae Jeong Oh
-
Publication number: 20140045709Abstract: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.Type: ApplicationFiled: December 27, 2012Publication date: February 13, 2014Inventors: Carlo M. Croce, George A. Calin
-
Patent number: 8649983Abstract: The present invention relates to a method and to compounds useable in the method for analysis of cells for the presence of an analyte and sorting the cells on the basis of the analyte. The compounds used in the method are optically detectable because of the content of a fluorochrome and contain a binder fraction which can specifically bind an analyte, in particular an oligonucleotide.Type: GrantFiled: July 15, 2009Date of Patent: February 11, 2014Assignee: Masterrind, GmbHInventors: Detlef Rath, Wilfried Kues, Ulrike Taylor, Stephan Barcikowski, Svea Petersen
-
Patent number: 8648186Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.Type: GrantFiled: March 15, 2013Date of Patent: February 11, 2014Assignee: Nogra Pharma LimitedInventor: Giovanni Monteleone
-
Publication number: 20140038835Abstract: The present invention features a method for diagnosing hypertrophic cardiomyopathy by detecting one or more single nucleotide polymorphisms (SNPs) of the formin homology 2 domain containing 3 gene (FHOD3).Type: ApplicationFiled: August 12, 2011Publication date: February 6, 2014Inventors: Gordon Huggins, Martin Maron
-
Publication number: 20140037647Abstract: Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.Type: ApplicationFiled: March 28, 2012Publication date: February 6, 2014Applicant: CORNELL UNIVERSITYInventors: Mark A. Rubin, Himisha Beltran
-
Patent number: 8642753Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.Type: GrantFiled: August 3, 2012Date of Patent: February 4, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
-
Publication number: 20140031246Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to diagnose and monitor various diseases such as cancer.Type: ApplicationFiled: July 22, 2011Publication date: January 30, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Stephen J. Meltzer, Jee-Hoon Song, Yulan Cheng
-
Patent number: 8637482Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: GrantFiled: June 7, 2010Date of Patent: January 28, 2014Assignee: Quark Pharmaceuticals, Inc.Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Patent number: 8637654Abstract: This invention relates to a ribonucleic acid (RNA) based assay system for body fluid identification, and in particular to a novel, multiplex, parallel assay system based on messenger RNA expressed in human tissue, and to a method for using the same.Type: GrantFiled: September 1, 2009Date of Patent: January 28, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: John Ballantyne, Jane Juusola
-
Patent number: 8637245Abstract: The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation.Type: GrantFiled: July 20, 2007Date of Patent: January 28, 2014Assignee: Pangea Biotech, S.A.Inventors: Rafael Rosell Costa, Miguel Taron Roca
-
Patent number: 8637244Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.Type: GrantFiled: December 5, 2007Date of Patent: January 28, 2014Assignee: deCODE Genetics ehf.Inventors: Anna Helgadottir, Daniel Gudbjartsson
-
Publication number: 20140024557Abstract: The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis.Type: ApplicationFiled: October 1, 2013Publication date: January 23, 2014Applicant: The Regents of the University of CaliforniaInventor: Linda C. Giudice
-
Publication number: 20140024099Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.Type: ApplicationFiled: July 18, 2013Publication date: January 23, 2014Inventors: Ryan D. Morin, Marco A. Marra, Randy D. Gascoyne, Joseph M. Connors
-
Publication number: 20140018528Abstract: A method to measure enhancement in the quality of life of an animal fed a super senior pet food composition comprising quantitating the gene expression levels of one or more genes in said animal and comparing said levels in the animal to levels in the animal prior to administration of said super senior pet food composition. A method to enhance the quality of life of an animal by modulating the expression level of one or more genes in said animal in order to mimic the pattern of expression seen in vivo after administration of a super senior pet food composition.Type: ApplicationFiled: September 24, 2013Publication date: January 16, 2014Applicant: Hill's Pet Nutrition, Inc.Inventors: Ryan Michael Yamka, Kim Gene Friesen
-
Publication number: 20140017774Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicants: The Johns Hopkins University, Stichting Katholieke Universiteit, more particularly The Univ. Medical Centre NijmegenInventors: Marion J.G. Bussemakers, William B. Isaacs
-
Publication number: 20140017686Abstract: The present invention aims at providing a method for assessing risk of hepatocellular carcinoma with high sensitivity and specificity. Extracted were 30 regions containing 45 CpG sites which have DNA methylation levels significantly different between in normal liver tissue samples and in noncancerous liver tissue samples from patients with hepatocellular carcinoma. It was found that the noncancerous liver tissue samples from patients with HCC were able to be assessed for risk of hepatocellular carcinoma by setting cutoff values for distinguishing between the normal liver tissue samples and the noncancerous liver tissue samples from patients with HCC for the extracted 30 regions.Type: ApplicationFiled: January 27, 2012Publication date: January 16, 2014Applicant: NATIONAL CANCER CENTERInventors: Yae Kanai, Eri Arai, Ryo Nagashio
-
Patent number: 8629262Abstract: A method and a kit for the identification of chromosomal inversions are described. Single-stranded sister chromatids are generated, for example by CO-FISH. A plurality of non-repetitive, labeled probes of relatively small size are hybridized to portions of only one of a pair of single-stranded sister chromatids. If no inversion exists, all of the probes will hybridize to a first chromatid. If an inversion has occurred, these marker probes will be detected on the sister chromatid at the same location as the inversion on the first chromatid.Type: GrantFiled: November 14, 2011Date of Patent: January 14, 2014Assignees: Colorado State University Research Foundation, Board of Regents of the University of Texas SystemInventors: Susan M. Bailey, F. Andrew Ray, Edwin H. Goodwin, Joel S. Bedford, Michael N. Cornforth
-
Patent number: 8629117Abstract: Medicament comprising a combination of at least one inhibitor of the effect of a substance negatively effecting an immune response, the substance selected from the group consisting of TGF-? and its receptors, VEGF and its receptors, interleukin 10 (IL-10) and its receptors, PGE2 and its receptors, wherein the inhibitor has a molecular weight of less than 100 kDa and at least one stimulator positively effecting an immune response.Type: GrantFiled: September 7, 2007Date of Patent: January 14, 2014Assignee: Biognostik Gesellschaft fur biomolekulare Diagnostik mbHInventors: Karl-Hermann Schlingensiepen, Reimar Schlingensiepen, Wolfgang Brysch
-
Patent number: RE44760Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.Type: GrantFiled: September 27, 2012Date of Patent: February 11, 2014Assignee: Genzyme CorporationInventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier